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Over-excitabilityAlthough the sodium channel blockermexiletine is considered the ﬁrst-line drug inmyotonia, some patients ex-
periment adverse effects, while others do not gain any beneﬁt. Other antimyotonic drugs are thus needed to offer
mexiletine alternatives. In the present study, we used a previously-validated rat model of myotonia congenita to
compare six marketed sodium channel blockers to mexiletine. Myotonia was induced in the rat by injection of
anthracen-9-carboxylic acid, a muscle chloride channel blocker. The drugs were given orally and myotonia was
evaluated by measuring the time of righting reﬂex. The drugs were also tested on sodium currents recorded in
a cell line transfected with the human skeletal muscle sodium channel hNav1.4 using patch-clamp technique.
In vivo, carbamazepine and propafenone showed antimyotonic activity at doses similar to mexiletine (ED50
close to 5 mg/kg); ﬂecainide and orphenadrine showed greater potency (ED50 near 1 mg/kg); lubeluzole and
riluzolewere themore potent (ED50 near 0.1 mg/kg). The antimyotonic activity of drugs in vivowas linearly cor-
related with their potency in blocking hNav1.4 channels in vitro. Deviation was observed for propafenone and
carbamazepine, likely due to pharmacokinetics and multiple targets. The comparison of the antimyotonic dose
calculated in rats with the current clinical dose in humans strongly suggests that all the tested drugs may be
used safely for the treatment of humanmyotonia. Considering the limits of mexiletine tolerability and the occur-
rence of non-responders, this study proposes an arsenal of alternative drugs, which may prove useful to increase
the quality of life of individuals suffering from non-dystrophic myotonia. Further clinical trials are warranted to
conﬁrm these results.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
Myotonic disorders are characterized by skeletal muscle stiffness
after voluntary contraction or percussion. Inherited myotonias include
dystrophic and non-dystrophic diseases and can be subdivided in vari-
ous disease entities on the basis of clinical phenotype and genotype
(Matthews et al., 2010; Rayan and Hanna, 2010; Trivedi et al., 2013b).
Non-dystrophic myotonias (NDM) are caused by mutations in genes
encoding the voltage-dependent chloride channel (CLCN1 gene, ClC-1
protein) or sodium channel (SCN4A gene, Nav1.4 protein), which are
expressed exclusively in skeletal muscles. The reduced activity of mu-
tated ClC-1 channels or increased activity of mutated Nav1.4 channels
determine a pathological sarcolemma hyperexcitability with occur-
rence of high-frequency action potential discharges; the consequent dif-
ﬁculty in muscle relaxation is responsible for the characteristic stiffness
of myotonic muscle. NDM can be chronically debilitating due to painScienze del Farmaco, Università
0125 Bari, Italy. Fax: +39 080
esaphy).
. This is an open access article underand muscle stiffness, which are associated with frequent falls and dis-
ability. In the more severe cases, myotonia can prohibit sport practice,
limit ability at school, and alter physical growth.
Pharmacotherapy is often needed for myotonic patients. Today, the
class IB antiarrhythmic, mexiletine, is considered as the drug of choice.
By blocking skeletal muscle sodium channels, mexiletine can contrast
high frequency ﬁring ofmyotonic action potentials. Recent clinical trials
have conﬁrmed the usefulness of mexiletine in both dystrophic and
non-dystrophic myotonias, irrespective of the culprit gene (Logigian
et al., 2010; Statland et al., 2012). Consequently,mexiletinewas recently
appointed by FDA and EMA as an orphan drug in NDM.Mexiletine pref-
erentially binds the open and/or inactivated sodium channels, resulting
in a use-dependent block that is thought to constitute the basis of the
selective action of mexiletine on pathologic hyperactive tissues (Conte
Camerino et al., 2007; Desaphy et al., 1999; Wang et al., 2004).
Nevertheless not all the myotonic individuals obtain beneﬁts from
mexiletine, because the drug can induce side effects limiting patient
compliance (mainly epigastric discomfort, nausea, tremor, anxiety,
dizziness, lightheadedness, and headaches). Particular attention
must be also paid to cardiomyopathic patients, who may be exposed
to life-threatening complications. In addition, non responders tothe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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pharmacogenetic mechanisms (Desaphy et al., 2001, 2013a, 2013b,
2013c). Last but not least, mexiletine was withdrawn from the
market in several countries, leaving patients and doctors with an
unmet medical need. It is thus likely that a number of myotonic indi-
viduals would obtain signiﬁcant improvement of quality of life from
the individuation of new efﬁcient and safe antimyotonic drugs.
Other sodium channel blockers have been anecdotally reported
to exert antimyotonic activity, including carbamazepine, ﬂecainide,
and propafenone, although no randomized clinical trial has been per-
formed in NDM (Alfonsi et al., 2007; Desaphy et al., 2013a; Lyons et al.,
2010; Rosenfeld et al., 1997; Savitha et al., 2006; Sechi et al., 1983).
Flecainide and propafenone resulted efﬁcient in patients with speciﬁc
sodium channel mutations, who were resistant to mexiletine (Alfonsi
et al., 2007; Desaphy et al., 2013a; Rosenfeld et al., 1997). Nevertheless,
there is no available information regarding the relative efﬁciency of
these drugs in the whole myotonic population. It is worth to note that
no chloride channel openers are available.
Starting from these considerations, we have recently developed a
preclinical rat model of myotonia in vivo to allow drug screening
(Desaphy et al., 2013b). In this model, inhibition of the ClC-1 chlo-
ride channel by anthracen-9-carboxylic acid (9AC) induces muscle
stiffness that increases the time of righting reﬂex (TRR) of the rat.
Thus we were able to quantitatively assess the in vivo antimyotonic
activity of orally-administrated mexiletine and β-adrenergic drugs
that also block sodium channels in a use-dependent manner
(Desaphy et al., 2003, 2013b).
In the present study, we used this preclinical model to evaluate
in vivo the antimyotonic activity of a number ofmarketed sodium chan-
nel blockers. The tested drugswere chosen because theywere previous-
ly reported to relieve myotonia in humans (mexiletine, carbamazepine,
ﬂecainide, and propafenone) (Alfonsi et al., 2007; Desaphy et al., 2013a;
Lyons et al., 2010; Rosenfeld et al., 1997; Savitha et al., 2006; Sechi et al.,
1983), and/or to exert signiﬁcant block of human skeletal muscle so-
dium channels in cell lines (orphenadrine, lubeluzole, and riluzole)
(Desaphy et al., 2001, 2004, 2009, 2012, 2013c). Patch clamp exper-
iments were performed to verify the correlation between use-
dependent block of heterologously-expressed hNav1.4 channels
and antimyotonic efﬁciency in vivo.
Materials and methods
Animal care and in vivo experiments
The experiments were performed in accordance with the Italian
Guidelines for the use of laboratory animals, which conforms to the
European Union Directive for the protection of experimental animals
(2011/63/EU), and received approval from the Animal Experimentation
Ethic Committee of the University of Bari (CESA prot. 7/12) and Italian
Health Department (Decreto n. 91/2013-B). All efforts were made to
minimize animal suffering and to reduce the number of animals used.
Adult WISTAR rats (350–500 g) purchased from Charles River—Italy
were housed individually and given food and water ad libitum. In a
typical daily experiment, three/four rats were randomly assigned to re-
ceive an intraperitoneal injection of 30 mg/kg anthracen-9-carboxylic
acid (9AC), as previously described (Desaphy et al., 2013b). Ten
minutes after 9-AC injection, the animals were given drug or vehicle
per os using an esophageal cannula. Myotonia state was assayed by
measuring the time of righting reﬂex (TRR), that is the time taken by
the rat to turn back on his four limbs after having been positioned in
supine position. Ambient temperature was maintained to 20–22 °C.
The TRR was determined 10 min before and 10, 30, 60, 120, and
180 min after 9AC administration. At each time point, the TRR was cal-
culated as the average of 7 trials, which allows obtaining a S.E.M. minor
than 10% of the mean. A 1-minute interval was respected between two
trials to avoid any warm-up phenomenon. Typically, a control rat takesless than 0.5 s to turn back on his limbs, whereas, 30 min after 9AC in-
jection, a myotonic rat shows a TRR greater than 3 s. An antimyotonic
drug is expected to reduce the TRR with respect to vehicle. Effect of
9AC was maximal 30 min after injection and reversed spontaneously
within 15 h. At the end of each experimental day, the tested rats
were allowed a resting period of at least 48 h before to reintegrate
the reserve pool. A number of experiments have been performed
blindly, meaning that the two operators who measured the TRR in
the four rats in the daily experiment were not aware of the drug
dose given to each rat. No apparent difference was found between
blind and open experiments.
This protocol was used to evaluate the time course of drug effects
at each dose. For each drug dose, the protocols were repeated on
three-to-four days in different rats, and the experimental points
are given as the mean ± S.E.M. Statistical analysis was performed
by ANOVA followed by ad-hoc Bonferroni's t-test to compare differ-
ences between drug doses at each time point. Differences were con-
sidered signiﬁcant with P b 0.05. The dose–response relationships
were drawn by reporting the mean TRR measured at each drug
dose normalized with respect to the mean TRR measured with drug
vehicle as a function of the drug dose. The relationships were ﬁt
with equation reported in ﬁgure legend.
Sodium current measurement in HEK293 cells
Whole-cell sodium currents (INa) were recorded with patch-clamp
technique in HEK293 cells permanently transfected with the human
skeletal muscle isoform of voltage-gated sodium channel, hNav1.4
(Desaphy et al., 2012). Sodium current recordings were performed
at room temperature (20–22 °C) using an Axopatch 1D ampliﬁer
(Axon Instruments, Union City, CA, USA). Voltage clamp protocols
and data acquisition were performed with pCLAMP 9.2 software
(Axon Instruments) through a 12-bit A-D/D-A interface (Digidata
1340, Axon Instruments). Pipettes made with Corning 7052 glass
(Garner Glass, Claremont, CA, USA) had resistance that ranged from 1
to 3 MΩ. Currents were low-pass ﬁltered at 2 kHz (−3 dB) by the
four-pole Bessel ﬁlter of the ampliﬁer and digitized at 10–20 kHz.
After the rupture of patch membrane, a test pulse of−30 mV from a
holding potential of−120mVwas applied to the cell until stabilization
of sodium current amplitude and kinetics (typically 5 min). Only those
data obtained from cells exhibiting voltage errors b5mV after series re-
sistance compensation were considered for analysis. Little (b5%) or no
rundown was observed within the experiments.
Drugs and solutions
Patch clamp pipette solution contained in mM: 120 CsF, 10 CsCl,
10 NaCl, 5 EGTA and 5 HEPES, and pHwas set to 7.2 with CsOH. Bath so-
lution for patch clamp recordings contained (inmM): 150 NaCl, 4 KCl, 2
CaCl2, 1 MgCl2, 5 HEPES and 5 glucose. The pH was set to 7.4 with
NaOH. All the compounds were purchased from Sigma-Aldrich (Milan,
Italy).
Mexiletinehydrochloride, anthracen-9-carboxylic acid (9AC), carba-
mazepine, carbamazepine 10,11-epoxide (epo-CBZ), propafenone
hydrochloride, ﬂecainide acetate, orphenadrine hydrochloride, were
purchased from Sigma-Aldrich (Milan, Italy). Lubeluzole (R,S racemate)
and riluzolewere synthesized in themedicinal chemistry laboratories of
our department as previously described (Bruno et al., 2006; Catalano
et al., 2013; Desaphy et al., 2013c).
For patch-clamp experiments, the drugs were dissolved at the
desired ﬁnal concentration in external patch solution containing up to
1% dimethylsulfoxide. In our experimental conditions, we found no
effect of 1% DMSO on sodium channels. Notwithstanding, control re-
cordings weremade in cells bathed with drug-free solutions containing
the same amount of DMSO. The patched cell was continuously exposed
to a stream of control (supplemented with DMSO as needed) or drug-
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in vivo experiments, a solution containing 2.4 g/l of 9AC was prepared
each day in distilled water and 0.3% bicarbonate; the volume of i.p. in-
jection was adjusted to get 30 mg/kg body weight (Desaphy et al.,
2013b). Exploratory drugs were diluted at the desired concentration
directly in physiological 0.9% NaCl saline for oral administration of a
volume close to 1 ml.
Results
Antimyotonic effects of marketed drugs in the rat model of myotonia
Myotonia was induced in rats by intraperitoneal injection of
30 mg/kg 9AC and was evaluated by measuring the TRR. As detailed
elsewhere, such a method allows a quantitative appreciation of re-
producible myotonia (Desaphy et al., 2013b). Ten minutes after
9AC injection the TRR was dramatically prolonged from b0.5 to
~2 s, and increased further to ~4 s 30 min after. Then the TRR de-
creased gradually over time, being ~1 s 3 h after 9AC. Drugs or vehi-
cle was administrated orally to the rats 20 min after 9-AC injection.
The TRR measured at each time point was normalized as a function
of TRRmeasured 10min after 9AC injection to comparemyotonia be-
tween rats receiving the various drugs or vehicle.
The dose-dependent effects of the exploratory drugs are shown in
Fig. 1 and statistical analysis is reported in Supplementary Fig. S1.
Compare to vehicle, doses greater than 1 mg/kg of mexiletine,
propafenone, or carbamazepine signiﬁcantly reduced the TRR mea-
sured 30 min after 9AC. Both ﬂecainide and orphenadrine exerted
signiﬁcant antimyotonic effect at doses superior to 0.3 mg/kg.
Lubeluzole and riluzole resulted as the most potent drugs, with a sig-
niﬁcant reduction of TRR observed at the dose of 0.1 mg/kg. Drug ef-
fects were dose-dependent but saturated at the highest doses,
without allowing a complete recovery of TRR. At the highest doses,
the drugs still exerted a signiﬁcant reduction of the TRR 60 min
after 9AC injection (i.e. 40 min after drug administration), but little or
no effect was observed then after. The TRR measured 30 min after 9AC
injection in the presence of drugs was normalized with respect to that
measured in the presence of vehicle to draw the dose–response curves
for each drugs. The half-maximumefﬁcient doses (ED50) are reported in
Table 1. The drugs are distributed in three groups with ED50 values
around 5 mg/kg (mexiletine, propafenone, carbamazepine), 1 mg/kg
(orphenadrine and ﬂecainide), and 0.1 mg/kg (lubeluzole and riluzole).
The maximal effect reached about 80% of TRR reduction for mexiletine
and ﬂecainide, and ~70% for all the other drugs.
Block of skeletal muscle Nav1.4 channels by antimyotonic drugs
For many of the tested drugs, the block of heterologously expressed
hNav1.4 channels has been evaluated by patch-clamp technique in pre-
vious studies, using rigorously identical voltage clamp protocols. Sodi-
um currents were elicited by depolarizing the cells from the holding
potential of−120 mV to a 30 ms-long test pulse at−30 mV. Sodium
current inhibition by drugs was measured at both 0.1 and 10 Hz stimu-
lation frequencies (Desaphy et al., 2004, 2009, 2012, 2013c). Here we
completed these experiments for propafenone and carbamazepine
(CBZ). Examples of sodium current traces are shown in Fig. 2, which
were recorded before (CTRL) and at the steady-state of drug block,
i.e. 3 min after drug application at 0.1 Hz, and between the 100th
and 110th pulse at 10 Hz. Propafenone, at the concentration of
10 μM, reduced peak current by 36 ± 8% at 0.1 Hz and by 74 ± 6%
at 10 Hz (n = 4) (Fig. 2A). Carbamazepine, at the concentration of
300 μM reduced peak current by 27 ± 5% at 0.1 Hz and by 42 ± 7%
at 10 Hz (n= 4) (Fig. 2B). The concentration–response relationships
were ﬁtted to evaluate the half-maximum inhibitory concentration
(Fig. 2C). The IC50 values for CBZ and propafenone are reported in
Table 2, together with the IC50 values previously determined forthe other drugs in exam. At 0.1 Hz stimulation frequency, the less
potent in blocking sodium currents was carbamazepine, followed by
mexiletine, orphenadrine and ﬂecainide, riluzole and lubeluzole, while
the more potent was propafenone. The drugs presented with different
use-dependent properties, thus the order of potency at 10 Hz was,
from the less to the more potent, CBZ b riluzole ~ ﬂecainide b
mexiletine b orphenadrine b propafenone b lubeluzole.
It has been proposed that the CBZ metabolite, carbamazepine-
10,11-epoxide (epo-CBZ), may be able to exert signiﬁcant pharma-
cological effect through sodium channel blockade (McLean and
Macdonald, 1986; Yoshimura et al., 1998). In an attempt to ﬁnd an
explanation for the disconnection between CBZ effects in vitro and
in vivo, we tested epo-CBZ on hNav1.4 sodium currents (Fig. 2D). Sodi-
um current inhibition exerted by 300 μM of the metabolite at 0.1 Hz
(22.1 ± 9%, n= 4) and 10 Hz (33.8 ± 13%, n= 4)was not signiﬁcantly
different from that exerted by the same concentration of CBZ (P N 0.05,
unpaired Student's t test). The dose–response curve was not construct-
ed for epo-CBZ, since the metabolite was poorly soluble at concentra-
tions greater than 300 μM.
We further evaluated the effects of drugs on sodium currents
using a voltage-clamp protocol that mimics more closely the myo-
tonic condition (Fig. 3). The holding potential was ﬁxed to −90 mV
(near the restingmembrane potential of muscle ﬁbers) and the sodium
currents were elicited by test pulses at−30 mV applied at the stimula-
tion frequency of 50 Hz (myotonic discharges have frequencies ranging
from tens to hundreds of Hz). The test pulses were 5 ms long, recalling
the action potential duration. In these conditions, a use-dependent re-
duction of sodium currents developed in the absence of drugs (UDB-C,
33 ± 5% reduction, n = 10). A representative example of 10 μM-
mexiletine effects is shown in Fig. 3A. In this cell, the UDB-C was
34.6%. At the frequency of 0.1 Hz, a little tonic block was observed
after application of mexiletine (TB, 9.5% reduction). In the presence of
the drug, a huge use-dependent reduction was measured at 50 Hz
(UDB-D, 66.7% reduction). The time course of use-dependent effects in
the presence and absence of 10 μMmexiletine (n = 3), as well as the
tonic and use-dependent block (TB + UDB) directly attributable to
the drug, which was obtained by subtraction is illustrated in Fig. 3B.
These latter values were calculated for the entire set of drugs and re-
ported as a function of drug concentration (Fig. 3C). Interestingly,
both carbamazepine and riluzole that showed little use-dependence be-
tween 0.1 and 10 Hz stimulation at the holding potential of−120 mV,
exerted a signiﬁcant use-dependent block in myotonia-like conditions.
The IC50 values, approximated as the intercept of the relationships
with 50% TB + UDB, are reported in Table 2. In these conditions,
the order of potency was, from the less to the more potent, CBZ b
epo-CBZ b mexiletine b orphenadrine ~ ﬂecainide b propafenone b
riluzole b lubeluzole.
Discussion
This study demonstrates that many sodium channel blockers can
exert antimyotonic activity in vivo. The rat model of myotonia was pre-
viously validated by testing the antimyotonic activity of mexiletine and
β-adrenergic drugs able to block sodium channels or not (Desaphy et al.,
2003, 2013b). In this previous study, propranolol and clenbuterol were
shown to exert signiﬁcant hNav1.4 sodium channel blockade in vitro
and antimyotonic activity in the rat. Nevertheless, the ED50 values for
both adrenergic drugs were close to 20 mg/kg in the rat, which is great-
er than the usual clinical dose in humans. All the sodium channel
blockers tested in the present study were more potent than mexiletine
in vivo. In an attempt to translate the effects measured in the rat model
to the clinics, we compared the ED50 values measured in rats to the re-
ported antimyotonic dose in humans (Table 1). During the clinical trial
in NDM, mexiletine was given to patients at the daily dose of 600 mg
(Statland et al., 2012), which corresponds to 8.6 mg/kg for 70 kg body
weight and is close to the ED50 value for antimyotonic activity in the
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Fig. 1. In vivo antimyotonic effects of exploratory drugs in the ratmodel ofmyotonia. The time course of normalized TRRvalueswas determined in 9AC-treated rats receiving various doses
of propafenone, carbamazepine, ﬂecainide, orphenadrine, lubeluzole, riluzole, and mexiletine. Each data point is the mean ± S.E.M. calculated from 3-to-4 rats. Statistical analysis of dif-
ferences between drug doses was performed at each time point with ANOVA followed by ad-hoc Bonferroni's t-test and results are reported in Supplementary Fig. S1. The dose–response
curvewas constructed for all the drugs by reporting the value of normalized TRR (expressed as percentage of the TRR calculated in rat receiving drug vehicle alone),measured 10min after
drug administration (i.e. 30 min after 9AC injection). The dose–response curve was ﬁtted with equation TRR =min + (100 min) / [1 + exp([Drug] / ED50)nH], where [Drug] is the drug
dose, ED50 value is the half-maximum efﬁcient dose, nH is the slope factor, and min the curve baseline. Values of ﬁt parameters ± the S.E. of the ﬁt are given in Table 1.
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et al., 2007), while the ED50 value calculated in the rat was three fold
minor than the daily dose reported in humans for carbamazepine
(Sechi et al., 1983) and ﬂecainide (Desaphy et al., 2013a). There is no re-
port about the use of orphenadrine and riluzole in myotonia therapy,
but these drugs are used in humans for other indications. Interestingly,Table 1
In vivo antimyotonic potency in the rat model and usual clinical doses in humans.
Drug ED50 (mg/kg) nH Min
Mexiletine 7.0 ± 1.4 1.2 ± 0.2 18.
Propafenone 4.4 ± 1.1 1.5 ± 0.6 31.
Carbamazepine 3.2 ± 0.7 1.9 ± 0.7 35.
Flecainide 0.8 ± 0.1 3.2 ± 1.8 18.
Orphenadrine 1.0 ± 0.2 2.0 ± 0.8 34.
Lubeluzole 0.12 ± 0.01 2.8 ± 0.8 28.
Riluzole 0.10 ± 0.01 2.8 ± 1.4 32.
The half-maximumefﬁcient dose (ED50), the slope factor (nH), and theminimal value of TRR (m
myotonia as shown in Fig. 1. Each value is reported ±S.E. of the ﬁt. The reported clinical dose u
brackets) are expressed in mg/kg/day, considering a body weight of 70 kg.the ED50 value for antimyotonic activity in the rat model was six-to-ten
fold lower than the usual dose in humans, suggesting that these drugs
can likely be used safely by myotonic patients (Table 1). Lubeluzole
has been used in humans as a neuroprotectant in stroke, but clinical tri-
als failed to conﬁrm its usefulness in this setting (Gandolfo et al., 2002).
At the clinical dose of 10 mg/day (close to the antimyotonic ED50 valueUsual clinical dose in humans
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1 ± 2.4 10 mg/day→ 0.14 mg/kg/day (neuroprotectant)
5 ± 4.5 100 mg/day→ 1.4 mg/kg/day (Amyotrophic Lateral Sclerosis)
in)were calculated from theﬁt of dose–response relationships obtained in the ratmodel of
sed in myotonic patients (references are given in the text) or other clinical indications (in
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Fig. 2. Effects of propafenone, carbamazepine, and carbamazepine-10,11-epoxide, on hNav1.4 sodium channel subtype. (A–C) Sodium currents were measured in HEK293 cells perma-
nently transfected with the human skeletal muscle hNav1.4 isoform using the whole-cell patch-clamp method. Currents were elicited by depolarizing the cells for 20 ms at−30 mV
fromaholding potential of−120mV, every 10or 0.1 s (i.e. 0.1Hz or 10Hz stimulation frequency, respectively). Sodiumcurrent traces recorded in representative cells are shown in control
condition (CTRL) and after acute application of 10 μM propafenone, 300 μM carbamazepine, or 300 μM carbamazepine-10,11-epoxide, at 0.1 and 10 Hz. (D) Concentration–response re-
lationshipswere constructed at 0.1 and 10Hz frequency stimulation for propafenone and carbamazepine. Each point is themean± S.E.M. fromat least 3 cells. The relationshipswereﬁtted
with equation [IDRUG / ICTRL = 1 / {1 + ([DRUG] / IC50)nH}], where IC50 value is the half-maximum inhibitory concentration and nH is the slope factor. The nH values were comprised in
between 0.8 and 1.2. The calculated IC50 ± S.E. of the ﬁt is reported in Table 2.
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tion of QT interval (N450 ms); thus lubeluzole safety proﬁle deserves
further in-depth studies before to use it in myotonic patients.
In the present study, we were also interested at evaluating the rela-
tionship between sodium channel inhibition in vitro and antimyotonic
activity in vivo. Poor regression coefﬁcients were obtained when
plotting the ED50 values obtained in vivo in the rat model versus
the IC50 values measured at 0.1 or 10 Hz (not shown). In contrast,
a good linear correlation (r2 = 0.91) was obtained between the
IC50 values determined in myotonia-like conditions in vitro and theTable 2
In vitro potency in sodium channel block.
Drug IC50 (μM)
0.1 Hz, hp−120 mV 10 Hz, hp−120 mV 50 Hz, hp−90 mV
Mexiletine 246 ± 15 24 ± 2 20
Propafenone 13 ± 1 2.8 ± 0.3 1.5
Carbamazepine 701 ± 183 425 ± 64 100
epo-CBZ n.d. n.d. 70
Orphenadrine 93 ± 12 13 ± 1 5
Flecainide 84 ± 17 37 ± 6 4
Lubeluzole 31 ± 5 1.7 ± 0.2 0.3
Riluzole 50 ± 8 43 ± 3 0.9
The half-maximum inhibitory concentration (IC50) values at the holding potential (hp) of
−120 mV were calculated from the ﬁt of concentration–response relationships shown in
Fig. 2. Each value is reported ±S.E. of the ﬁt. The IC50 values for epo-CBZ were not deter-
mined. At the hp of−90 mV, the IC50 values were approximated by eyes as the intercept
of the concentration–response relationships with 50% of TB + UDB, as shown in Fig. 3C.ED50 values (Fig. 4), when considering all drugs but propafenone
and carbamazepine (or its metabolite). Indeed propafenone showed
a weak antimyotonic activity in vivo with respect to its activity on
sodium channels in vitro, whereas carbamazepine appearedmore ef-
ﬁcient in vivo than expected from in vitro experiments. The apparent
discrepancies for these two drugs are probably related to in vivo
pharmacokinetics or pharmacodynamics. In this regard, although
the metabolite epo-CBZ exerted a slightly greater sodium channel
blockade than carbamazepine, this appears insufﬁcient to account
for the disconnection between in vivo and in vitro effects. On the
other hand, although the maximal dose recommended in adults is
600 mg for both mexiletine and carbamazepine, the expected thera-
peutic range of plasma concentration is in between 4 and 12 μg/ml
for carbamazepine and 0.5–2 μg/ml for mexiletine, suggesting that
bioavailability of carbamazepine is about 6 fold superior. A carba-
mazepine concentration of 12 μg/ml corresponds to 51 μM, which
is close to the IC50 of carbamazepine (100 μM) and its active metab-
olite (70 μM) calculated in vitro. This observation suggests that phar-
macokinetics may contribute to the poor correlation between the
measured in vivo and in vitro effects of carbamazepine. Regarding
propafenone, besides sodium channel block, the drug is known to inhib-
it β-adrenergic receptors (Burnett et al., 1988). The β-adrenergic ago-
nists are known to stimulate the Na+, K+ pump, thereby inducing
hyperpolarization and increasing uptake of K+ in skeletal muscle
in vivo (Flatman and Clausen, 1976; Ford et al., 1995). It is widely ac-
knowledged that chloride channel myotonia develops because the low
chloride conductance in myotonia congenita patients cannot counter-
balance the depolarization stemming from K+ accumulation in T-
tubules (Adrian and Bryant, 1974; Cannon, 2001; Clausen, 2013).
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Fig. 3. Effects of exploratory drugs on hNav1.4 sodium channel subtype in myotonia-like conditions. Sodium currents were elicited in HEK293 cells permanently transfected with
the human skeletal muscle hNav1.4 isoform using the whole-cell patch-clamp method. To mimic a myotonia condition, the cells were depolarized for 5 ms (action potential du-
ration) at−30 mV from a holding potential of−90 mV (sarcolemma resting membrane potential), the stimulation frequency of 50 Hz (myotonic run frequency). (A) Sodium
current traces recorded in a representative cell are shown in control condition at 0.1 Hz (CTRL) and 50 Hz (use-dependent block in control, UDB-C) and after acute application of
10 μMmexiletine at 0.1 Hz (tonic block exerted by the drug, TB) and 50 Hz (use-dependent block observed in the presence of drug, UDB-D). (B) Time course of sodium current
peak amplitude reduction induced by 50 Hz stimulation in the absence of drug (UDB-C, triangles) and in the presence of 10 μMmexiletine (UDB-D, inverted triangles). The net
reduction induced by the drug was obtained by subtraction of UDB-C to UDB-D and addition of TB. The relationships represent the means from 3 cells; S.E.M. is not reported for
improving clarity of the graph. (C) Concentration–response relationships were constructed for all the exploratory drugs following the protocol shown in (B). Each point is the
mean ± S.E.M. from at least 3 cells. The half-maximum inhibitory concentration (IC50) values were approximated as the intercept of the relationships with 50% of (TB + UDB),
and are reported in Table 2.
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by propafenone may favor K+ accumulation in T-tubules, thereby
balancing the beneﬁcial effects of sodium channel inhibition onED50 (mg/kg)
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Fig. 4. Relationship between in vitro hNav1.4 sodium channel inhibition and in vivo
antimyotonic activity in the rat model. The IC50 values for sodium current inhibition
calculated in vitro in myotonia-like conditions (calculated as in Fig. 3) are reported
versus the ED50 value for in vivo antimyotonic activity in the rat model (measured
as in Fig. 1). For carbamazepine-10,11-epoxide (epo-CBZ), the ED50 value was mea-
sured for carbamazepine. The linear regression considering all the drugs (but epo-
CBZ) had a coefﬁcient r2 = 0.52 (not shown). The linear regression of all drugs except
epo-CBZ, carbamazepine, and propafenone, shows an r2 coefﬁcient of 0.91.myotonia. It is worth to note however that a recent study performed
on isolated muscles of myotonic mice suggested that depolarization
induced by increasing extracellular K+ concentration may contrast
myotonia (Hoppe et al., 2013). Further studies are warranted to clarify
the apparent discrepancies.
We can note that many sodium channel blockers display little se-
lectivity among neuronal and skeletal muscle channels. Although we
cannot exclude inhibition of neuronal sodium channels by the tested
drugs in our in vivo model, it is unlikely that such a block is determi-
nant for the antimyotonic activity, because myotonic hyperexcitability
is intrinsic to muscle ﬁbers.
In conclusion, the antimyotonic activity of drugs in vivo is well
correlated with their potency in blocking sodium channels in vitro
when using a myotonia-like condition. Signiﬁcant differences may
be present, such as for propafenone and carbamazepine, likely due to
pharmacokinetics andmultiple targets. By comparing the antimyotonic
dose calculated in rats and the current clinical dose in humans, it ap-
pears that all the tested drugs may be used safely for the treatment of
human myotonia (with some concern regarding lubeluzole). The re-
sults conﬁrm the antimyotonic activity of carbamazepine; this drug is
already considered by many as a second choice after mexiletine in
adults. Carbamazepine is sometimes preferred for treatment of younger
patients, because drug dosage and safety proﬁle are better deﬁned in
children. For instance, the drug has shown great efﬁcacy in severe neo-
natal episodic laryngospasm, a life-threatening form of sodium channel
102 J.-F. Desaphy et al. / Experimental Neurology 255 (2014) 96–102myotonia (Caietta et al., 2013; Lion-Francois et al., 2010). Flecainide and
propafenone are also already used bymyotonic patients carrying specif-
ic sodium channel mutations, who did not get satisfactory response
from mexiletine (Alfonsi et al., 2007; Desaphy et al., 2013a; Rosenfeld
et al., 1997). The present study suggests that these drugs may be efﬁ-
cient also in patients carrying chloride channel mutations. In addition
the results indicate that orphenadrine and riluzolemerit attention to in-
crease the number of therapeutic options.We previously demonstrated
that the sodium channel mutations may signiﬁcantly decrease channel
sensitivity tomexiletine,while effects ofﬂecainide are preserved, there-
by opening the way toward a pharmacogenetics strategy (Desaphy
et al., 2001, 2004, 2013a). It would be interesting to verify whether
hNav1.4 mutations modify channel sensitivity to the other examined
drugs. Considering the occurrence of mexiletine non-responders and
the limited tolerability of mexiletine in other patients, this study sets
the basis for the deﬁnition of an arsenal of alternative drugs, which
may prove useful to increase the quality of life of individuals suffering
from non-dystrophic myotonia. While the rat model of myotonia
congenita offers a valuable preclinical platform for testing antimyotonic
drug candidates, further clinical trials are warranted to conﬁrm these
results (Trivedi et al., 2013a).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.expneurol.2014.02.023.
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